https://www.selleckchem.com/products/ABT-888.html
Analyses were descriptive in nature, with higher scores reflecting better outcomes. Data from patients at the time of enrollment were analyzed. At baseline, patients initiating dulaglutide (N = 113 or liraglutide (N = 1051) rated their quality of life in terms of mean EQ-5D-5L index as 0.84 and 0.83, and in terms of mean EQ-VAS as 67.5 and 67.5, respectively. The mean baseline scores in patients initiating dulaglutide or liraglutide were 59.8 and 61.3 for IW-SP, 24.6 and 25.8 for DTSQs, 78.6 and 79.5 for DPM Life Productivity, and 87.
Like
Comment
Share
